Suppr超能文献

原发性乳腺癌的组织学分级和类固醇受体含量——对预后的影响及可能的作用方式

Histological grade and steroid receptor content of primary breast cancer--impact on prognosis and possible modes of action.

作者信息

Kamby C, Andersen J, Ejlertsen B, Birkler N E, Rytter L, Zedeler K, Thorpe S M, Nørgaard T, Rose C

机构信息

Department of Oncology, Finsen Institute, Rigshospitalet, Copenhagen, Denmark.

出版信息

Br J Cancer. 1988 Oct;58(4):480-6. doi: 10.1038/bjc.1988.245.

Abstract

The clinical course of breast cancer was related to degree of anaplasia (DA) and steroid receptor (SR) content of primary tumours in 743 patients (pts) with clinical recurrence, initially enrolled in the DBCG-77 protocols. The oestrogen receptor (ER) and the progesterone receptor (PgR) content was known in 110 and 67 pts. The recurrence-free interval, survival after recurrence, and the overall survival were all prolonged in patients with well differentiated tumours or with high SR content. The tumour growth rates were estimated as clinical rates of progression (i.e., the time elapsed from a single distant metastasis until dissemination). The progression rate was prolonged in relatively well differentiated as well as in receptor rich tumours. The extent of dissemination, as indicated by the number of metastatic sites, was not associated with either DA or SR content. However, the anatomical distribution of metastases varied with both DA and SR content: signs of poor prognosis (high DA or low SR content) were associated with occurrence of visceral metastases. In contrast, SR rich tumours had a propensity for recurrence in bone. The results suggest that the impact on prognosis of the features examined here includes both variations in growth rate and metastatic pattern.

摘要

在最初纳入DBCG - 77方案的743例临床复发患者中,乳腺癌的临床病程与原发肿瘤的间变程度(DA)和类固醇受体(SR)含量有关。110例患者已知雌激素受体(ER)含量,67例患者已知孕激素受体(PgR)含量。肿瘤分化良好或SR含量高的患者,其无复发生存期、复发后的生存期及总生存期均延长。肿瘤生长速率以临床进展速率估计(即从单个远处转移到播散所经过的时间)。在相对分化良好以及受体丰富的肿瘤中,进展速率延长。转移部位数量所表明的播散范围与DA或SR含量均无关。然而,转移的解剖分布随DA和SR含量而变化:预后不良的体征(高DA或低SR含量)与内脏转移的发生有关。相反,SR丰富的肿瘤倾向于在骨中复发。结果表明,此处所检查特征对预后的影响包括生长速率和转移模式的变化。

相似文献

本文引用的文献

2
3
Clinical application of estrogen receptor in breast cancer.雌激素受体在乳腺癌中的临床应用。
Cancer. 1980 Dec 15;46(12 Suppl):2932-8. doi: 10.1002/1097-0142(19801215)46:12+<2932::aid-cncr2820461439>3.0.co;2-0.
6
Estrogen receptor: a prognostic factor in breast cancer.
Cancer. 1981 Feb 1;47(3):554-60. doi: 10.1002/1097-0142(19810201)47:3<554::aid-cncr2820470322>3.0.co;2-w.
8
The pathogenesis of cancer metastasis.癌症转移的发病机制。
Nature. 1980 Jan 10;283(5743):139-46. doi: 10.1038/283139a0.
9
Assessment of response of bone metastases to systemic treatment in patients with breast cancer.乳腺癌患者骨转移对全身治疗反应的评估
Cancer. 1983 Aug 15;52(4):610-4. doi: 10.1002/1097-0142(19830815)52:4<610::aid-cncr2820520406>3.0.co;2-5.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验